GEO DataSets

(Submitter supplied) Background: In multiple sclerosis (MS), immune up-regulation is coupled to subnormal immune response to interferon-β (IFN-β) and low serum IFN-β levels. The relationship between the defect in IFN signalling and acute and long-term effects of IFN-β on gene expression in MS is inadequately understood. Methods: We profiled IFN-β-induced transcriptome shifts, using high-resolution microarrays on 227 mononuclear cell samples from IFN-β-treated MS Complete Responders (CR) stable for five years, and stable and active Partial Responders (PR), stable and active untreated MS, and healthy controls. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL17586

227 Samples

Download data: CEL

(Submitter supplied) The purpose of this study was to characterize the transcriptional effects induced by subcutaneous IFN-beta-1a treatment (Rebif, 22 µg or 44 µg three times a week) in patients with relapsing-remitting form of multiple sclerosis (MS). By using Affymetrix DNA microarrays, we obtained genome-wide expression profiles of peripheral blood mononuclear cells from 12 MS patients within the first two years of IFN-beta administration.

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL14837

60 Samples

Download data: CEL

(Submitter supplied) Transcriptome analysis of RNA samples from human PBMCs of IFN-beta treated multiple sclerosis patients. Interferon (IFN)-b-1a (Avonex) and longer half-life, polyethylene glycol-conjugated IFN-b-1a (PEG-IFN-b-1a, Plegridy), may generate different molecular responses. At 6 h, non-PEGylated IFN-b-1a injection upregulated expression of 136 genes and PEG-IFN-b-1a upregulated 85. At 24 h, induction was maximal; IFN-b-1a upregulated476 genes and PEG-IFN-b-1a now upregulated 598. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL24539

89 Samples

Download data: CEL, CHP, TAB

(Submitter supplied) We studied the gene expression patterns in PBMC from relapsing remitting MS patients undergoing weekly IFN-ß-1a therapy. On the basis of two fold changes in expression levels and statistical analyses we selected a diagnostic set of 137 genes that were differentially expressed between pretreatment and IFN-ß-1a-treated MS patients. Some these 137 genes may provide the basis for lack of IFN-ß-1a response. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Dataset:

GDS2419

Platform:

GPL4191

36 Samples

Download data

Analysis of peripheral blood mononuclear cells from relapsing-remitting multiple sclerosis (MS) patients 1 day before, 1 day after, and up to 12 months after the initiation of interferon beta-1a (IFN-beta-1a) therapy. Results identify biomarkers for beta-IFN responsiveness.

Organism:

Homo sapiens

Type:

Expression profiling by array, count, 2 agent, 2 disease state, 6 individual, 4 time sets

Platform:

GPL4191

Series:

GSE5574

36 Samples

Download data

(Submitter supplied) IFNb has been used as a first line therapy for relapsing remitting multiple sclerosis (RRMS). Since only a few studies have addressed the role of endogenous IFNb in the pathogenesis of the disease, our objective was to characterize its role in the transcriptional regulation of pathogenic Th17 cytokines in patients with RRMS. In-vitro studies have demonstrated that IFNb inhibited IL-17A, IL-17F, IL-21, IL-22 and IFN-b secretion in CD4+ lymphocytes through the induction of suppressor of cytokine secretion (SOCS)1 and 3. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Dataset:

GDS4994

Platform:

GPL570

12 Samples

Download data: CEL

Analysis of PBMCs from patients with clinically isolated syndrome suggestive of multiple sclerosis (CIS) after 12 months of IFNβ-1a treatment. All patients exhibited a favorable response to IFN-β-1a treatment. Results provide insight into the role of endogenous IFN-β in the pathogenesis of MS.

Organism:

Homo sapiens

Type:

Expression profiling by array, count, 6 individual, 2 protocol sets

Platform:

GPL570

Series:

GSE53716

12 Samples

Download data: CEL

(Submitter supplied) The purpose of this study was to characterize the transcriptional effects induced by subcutaneous IFN-beta-1b treatment (Betaferon, 250 µg every other day) in patients with relapsing-remitting form of multiple sclerosis (MS). By using Affymetrix DNA microarrays, we obtained genome-wide expression profiles of peripheral blood mononuclear cells from 25 MS patients within the first two years of IFN-beta administration.

Organism:

Homo sapiens

Type:

Expression profiling by array

Datasets:

GDS4145 GDS4146

Platforms:

GPL96 GPL97

250 Samples

Download data: CEL

(Submitter supplied) The purpose of this study was to characterize the transcriptional effects induced by intramuscular IFN-beta-1a treatment (Avonex, 30 µg once weekly) in patients with relapsing-remitting form of multiple sclerosis (MS). By using Affymetrix DNA microarrays, we obtained genome-wide expression profiles of peripheral blood mononuclear cells from 24 MS patients within the first four weeks of IFN-beta administration. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platforms:

GPL9741 GPL9742

144 Samples

Download data: CEL

Temporal analysis of PBMCs collected from 25 German relapsing-remitting multiple sclerosis patients treated with recombinant interferon-beta-1b (rIFN-β-1b, 250 µg every other day) for 2 years. Results provide insight into molecular mechanisms of IFN-b action.

Organism:

Homo sapiens

Type:

Expression profiling by array, count, 2 gender, 5 time sets

Platform:

GPL97

Series:

GSE24427

125 Samples

Download data: CEL

Temporal analysis of PBMCs collected from 25 German relapsing-remitting multiple sclerosis patients treated with recombinant interferon-beta-1b (rIFN-β-1b, 250 µg every other day) for 2 years. Results provide insight into molecular mechanisms of IFN-b action.

Organism:

Homo sapiens

Type:

Expression profiling by array, count, 2 gender, 5 time sets

Platform:

GPL96

Series:

GSE24427

125 Samples

Download data: CEL

(Submitter supplied) Since we found an upregulation of the long non coding RNA MALAT1 in Multiple Sclerosis (MS) patients, we decided to explore the global effect of MALAT1 modulation on transcriptome. We hence performed high-coverage RNA-seq experiments of MALAT1 knockdown in Jurkat E6-1 T cells to analyze gene expression, alternative splicing (AS), and backsplicing profiles. We found 107 differentially expressed genes, 1114 dysregulated AS events, and 49 circular RNAs that were modulated by MALAT1. more...

Organism:

Homo sapiens

Type:

Expression profiling by high throughput sequencing

Platform:

GPL18573

6 Samples

Download data: TXT

(Submitter supplied) To identify gene expression changes and pathways induced by interferon-β (IFN-β) in B cells, we studied the in vitro response of EBV-transformed B cells (lymphoblast cell lines-LCLs). LCLs were derived from an MS patient repository. Whole genome expression analysis identified 115 genes that were more than two-fold differentially up-regulated following IFN-β exposure, with over 50 novel IFN-β response genes. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL10558

32 Samples

Download data: TXT

(Submitter supplied) One of our new major finding among the genes that contributes to MS susceptibility is ICSBP1. The so called disease modifying therapies like interferon-beta (IFN-β), possibly acting on the peripheral T-cells, reduce the disease activity and the clinical progression, with a MRI-detectable effect in preventing lesion burden and cerebral atrophy development in RR-MS. It suggests a critical role of peripheral blood mononuclear cells (PBMCs) immune response and modulation in developing inflammation in the brain. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL570

240 Samples

Download data: CEL

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL16209

815 Samples

Download data: CEL

(Submitter supplied) Multiple sclerosis is the most common autoimmune disease of the central nervous system. Studying whole blood RNA from a cohort of 195 MS patients and 66 healthy controls, we identified gene expression signatures for interferon treatment and disease status by microarray analysis. Blood was collected at multiple time points (up to 3 for patients, 2 for controls). Patients were either untreated or treated with Interferon. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL16209

102 Samples

Download data: CEL

(Submitter supplied) Multiple sclerosis is the most common autoimmune disease of the central nervous system. Studying whole blood RNA from a cohort of 195 MS patients and 66 healthy controls, we identified gene expression signatures for interferon treatment and disease status by microarray analysis. Blood was collected at multiple time points (up to 3 for patients, 2 for controls). Patients were either untreated or treated with Interferon. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL16209

212 Samples

Download data: CEL

(Submitter supplied) Multiple sclerosis is the most common autoimmune disease of the central nervous system. Studying whole blood RNA from a cohort of 195 MS patients and 66 healthy controls, we identified gene expression signatures for interferon treatment and disease status by microarray analysis. Blood was collected at multiple time points (up to 3 for patients, 2 for controls). Patients were either untreated or treated with Interferon. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL16209

183 Samples

Download data: CEL

(Submitter supplied) Multiple sclerosis is the most common autoimmune disease of the central nervous system. Studying whole blood RNA from a cohort of 195 MS patients and 66 healthy controls, we identified gene expression signatures for interferon treatment and disease status by microarray analysis. Blood was collected at multiple time points (up to 3 for patients, 2 for controls). Patients were either untreated or treated with Interferon. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL16209

318 Samples

Download data: CEL

(Submitter supplied) Transcriptome analysis of RNA samples from human PBMCs of anti-CD20 therapy in multiple sclerosis patients. Anti-CD20 is a highly effective therapy for multiple sclerosis (MS), a disease with multiple abnormalities in function of B and T cells and innate immune cells. Anti-CD20 therapy depletes B cells, which alters antibody production and has diverse effects on B cell immunity. These changes potentially affect immunity beyond B cells in MS. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL24539

44 Samples

Download data: CEL, CHP, TAB